Irbesartan
- Generic Name
- Irbesartan
- Brand Names
- Avalide, Avapro, Ifirmacombi, Karvea, Karvezide, Irbesartan Teva, Ifirmasta (previously Irbesartan Krka), Irbesartan Zentiva (previously Irbesartan Winthrop), Aprovel
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N6O
- CAS Number
- 138402-11-6
- Unique Ingredient Identifier
- J0E2756Z7N
- Background
Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy. It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry co...
- Indication
Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria. A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled ...
- Associated Conditions
- Diabetic Nephropathy, Hypertension
- Associated Therapies
- -
Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2011-01-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 108
- Registration Number
- NCT00529750
Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan
- First Posted Date
- 2007-08-16
- Last Posted Date
- 2007-08-16
- Lead Sponsor
- Università degli Studi dell'Insubria
- Target Recruit Count
- 80
- Registration Number
- NCT00517322
- Locations
- 🇮🇹
University of Insubria-Department of Clinical Medicine, Varese, Italy
Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing
- Conditions
- Interventions
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2009-10-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT00443612
- Locations
- 🇨🇳
Sanofi-Aventis, Taipei, Taiwan
Irbesartan and Atenolol in Hypertensive Heart Disease
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 115
- Registration Number
- NCT00389168
- Locations
- 🇸🇪
Karolinska Institutet, Daprtment of Clinical Sciences, Danderyd Hospital, Cardiovascular Research Laboratory, Stockholm, Sweden
Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 44
- Registration Number
- NCT00352560
- Locations
- 🇪🇸
Local Institution, Madrid, Spain
Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions
- Conditions
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2008-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT00350038
- Locations
- 🇭🇺
Sanofi-aventis, Budapest, Hungary
Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure
- Conditions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2007-10-31
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 36
- Registration Number
- NCT00347087
- Locations
- 🇩🇪
Applied Cachexia Research, Cardiology Dept. Charite Medical School, Virchow Klinikum, Berlin, Germany
Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 192
- Registration Number
- NCT00334581
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Shanghai, China
Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria
- Conditions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2006-05-18
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 52
- Registration Number
- NCT00320879
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Copenhagen, Denmark
ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation
- Conditions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 440
- Registration Number
- NCT00296218
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.